XML 89 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration and License Agreements - Amgen, Inc. (Details)
Sep. 28, 2016
USD ($)
agreement
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Jul. 31, 2020
USD ($)
Sep. 30, 2018
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Contract liabilities   $ 866,000   $ 74,099,000    
Amgen | Olpasiran Agreement            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Number of agreements | agreement 2          
Upfront payment $ 35,000,000          
Proceeds from the sale of future royalties $ 21,500,000          
Milestone payments   55,000,000 $ 25,000,000   $ 20,000,000 $ 10,000,000
Contract liabilities   0        
Contract assets   0        
Amgen | Olpasiran Agreement | Maximum            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Additional remaining development regulatory and sales milestones payments   $ 535,000,000